ClinicalTrials.gg
CompletedNCT03765671Updated Aug 22, 2019

Elafibranor Pharmacokinetic Parameters in Hepatic Impaired Patients

A Phase 1 interventional study of Elafibranor in Hepatic Impairment, Liver Disease and Pharmacokinetics, sponsored by Genfit. Completed at 2 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-08-22.

Sponsored by Genfit · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Jun 2019, 7 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 368 studies in Liver Diseases with a site in United States — 45 open to participants now, 59 under way, 5 of them phase 3. Liver Diseases · United States.

Enrollment
157th of 269
30 · median 48
Started
2018
with 21 others
Phase 1
62 of 368
4 open now
Registered
222nd of 368
by date

Among the 368 studies in Liver Diseases with a site in United States, this one is the 157th largest by enrollment of the 269 interventional ones that give a count, is one of 22 that started in 2018, is one of 62 in phase 1, and was the 222nd registered.

Liver Diseases

825 studies on the registry are indexed under Liver Diseases; 153 are open to participants now.

Browse Liver Diseases studies →

Open to participants now

45 of the 368 studies in Liver Diseases with a site in United States are open now. Recruiting first, the newest first:

40 more — sign in →

All 45 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Liver Diseases studies recruiting now, 51 (50%) set no upper age limit and 30 (29%) stop at 75 or younger; 19 take children under 18; 19 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 368 studies in Liver Diseases with a site in United States, or all of them as a file.
02

Study summary

This study is being conducted in order to assess the need for dose adjustment for elafibranor in patients with hepatic impairment. Pharmacokinetic parameters of elafibranor and its active metabolite (GFT1007) will be compared in hepatic impaired patients (mild, moderate and severe according to Child-Pugh categories) versus healthy participants after a single oral administration of elafibranor 120 mg.

03

Conditions studied

  • Hepatic Impairment
  • Liver Disease
  • Pharmacokinetics

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For all participants:
  1. Males or females, between 18 and 75 years of age, inclusive;
  2. With a minimum body weight of 50 kg and within a range of 18.0 to 40.0 kg/m², inclusive;
  3. Females participating in this study must be of non- or using highly efficient for the full duration of the study
  4. Negative serum pregnancy test at screening (if applicable);
  5. Negative antibody screens at Screening;

    • For hepatically impaired participants:
  6. Participants who have chronic (≥ 6 months) mild, moderate, or severe hepatic insufficiency (of any etiology) that has been clinically stable (no acute episodes of illness due to deterioration in hepatic function) for at least 1 month prior to Screening Currently on a stable medication regimen

    • For healthy volunteers with normal hepatic function:
  7. Non-smokers
  8. Matched to participants with Mild and/or Moderate and/or Severe hepatic impairment in age (± 10 years), BMI (± 20 percent) and gender.

Other protocol-defined inclusion criteria may apply

Exclusion criteria

Exclusion Criteria:

  • For all participants:
  1. A positive alcohol test result at Check-in;
  2. A history of alcohol abuse in the prior 2 years;
  3. Positive urine screen for drugs of abuse at Screening or Check-in.
  4. Strenuous exercise within 72 hours prior to Check-in;
  5. Blood donation or loss of blood (excluding volume drawn at screening or menses) of 50 mL to 499 mL of blood within 30 days, or more than 499 mL within 56 days prior to the dosing;
  6. History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs except that appendectomy and hernia repair will be allowed. Bariatric surgery will not be allowed.
  7. Presence or history of within the prior 3 years, with the exception of treated basal cell or squamous cell carcinoma;
  8. Poor peripheral venous access;
  9. Receipt of blood products within 2 months prior to Check-in;

    • For hepatically impaired participants:
  10. History of unstable diabetes mellitus Subjects who have a transjugular intrahepatic portosystemic shunt and/or have undergone portacaval shunting;
  11. Participant has shown evidence of hepatorenal syndrome or has ≤ 60 mL/min Subject has required treatment for GI bleeding within the 6 months prior to Check in;
  12. Recent history of paracentesis (\< 3 months prior to Check-in);
  13. Participants with Wilson's disease, alpha-1 antitrypsin deficiency, glycogen storage diseases, or galactosemia;
  14. Participants with anemia secondary to hepatic disease, unless is ≥ 9 g/dL and anemia symptoms are not . Subjects must have ≥ 35 000 at screening and at Day -1;

    • For healthy volunteers with normal hepatic function:
  15. Significant history or clinical manifestation of any metabolic (including thyroid), allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular (including any prior history of cardiomyopathy or cardiac failure), gastrointestinal (GI), neurological, or psychiatric disorder;
  16. Positive serologic test for surface antigen or for virus antibody at Screening;
  17. Frequent headaches (> twice a month) and/or migraines, recurrent nausea and/or vomiting;
  18. Participants with symptomatic hypotension at Screening, whatever the decrease of blood pressure, or asymptomatic postural hypotension;
  19. Cholecystectomy

Other protocol-defined exclusion criteria may apply

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Mild Child-Pugh A

    Single oral dose of elafibranor 120mg

    Drug: Elafibranor

  • Experimental
    Moderate Child-Pugh B

    Single oral dose of elafibranor 120mg

    Drug: Elafibranor

  • Experimental
    Severe Child-Pugh C

    Single oral dose of elafibranor 120mg

    Drug: Elafibranor

  • Experimental
    Healthy

    Single oral dose of elafibranor 120mg

    Drug: Elafibranor

Interventions

  • 120mg oral single dose

    Also known as: GFT505

06

What researchers measure

Primary outcomes

  1. Area under curve from dosing time to last measurement (AUC(0-t)) of elafibranor and active metabolite

    In participants with mild, moderate and severe hepatic impairment compared to healthy volunteers

    Time frame: pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose. Additionally, after elafibranor administration at 288 and 384 hours for hepatic impaired patients

  2. Area under curve from dosing time to infinity (AUC(0-∞)) of elafibranor and active metabolite

    In participants with mild, moderate and severe hepatic impairment compared to healthy volunteers

    Time frame: pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose. Additionally, after elafibranor administration at 288 and 384 hours for hepatic impaired patients

Secondary outcomes

  1. Plasma pharmacokinetics: maximum plasma drug concentration (Cmax)

    for elafibranor and metabolites

    Time frame: pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose. Additionally, after elafibranor administration at 288 and 384 hours for hepatic impaired participants

  2. Plasma pharmacokinetics: elimination half-life (t1/2)

    for elafibranor and metabolites

    Time frame: pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose. Additionally, after elafibranor administration at 288 and 384 hours for hepatic impaired participants

  3. Plasma pharmacokinetics: apparent volume of distribution (Vd/F)

    for elafibranor

    Time frame: pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose. Additionally, after elafibranor administration at 288 and 384 hours for hepatic impaired participants

  4. Plasma pharmacokinetics: renal clearance (CLr)

    for elafibranor and metabolites

    Time frame: pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose. Additionally, after elafibranor administration at 288 and 384 hours for hepatic impaired participants

  5. Plasma pharmacokinetics: apparent non renal clearance (CLnr/F)

    for elafibranor

    Time frame: pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose. Additionally, after elafibranor administration at 288 and 384 hours for hepatic impaired participants

  6. Plasma pharmacokinetics: apparent total clearance (CL/F)

    for elafibranor

    Time frame: pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose. Additionally, after elafibranor administration at 288 and 384 hours for hepatic impaired participants

  7. Plasma pharmacokinetics: area under the plasma concentration-time curve extrapolated from time t to infinity as a percentage of total area under the plasma concentration-time curve (%AUCextra)

    for elafibranor and metabolites

    Time frame: pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose. Additionally, after elafibranor administration at 288 and 384 hours for hepatic impaired participants

  8. Plasma pharmacokinetics: area under curve from dosing time to last measurement (AUC(0-t)) of glucuronide metabolites and corresponding aglycones

    for the glucuronide metabolites of elafibranor and corresponding aglycones

    Time frame: pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose. Additionally, after elafibranor administration at 288 and 384 hours for hepatic impaired participants

  9. Plasma pharmacokinetics: area under curve from dosing time to infinity (AUC(0-∞)) of glucuronide metabolites and corresponding aglycones

    for the glucuronide metabolites of elafibranor and corresponding aglycones

    Time frame: pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose. Additionally, after elafibranor administration at 288 and 384 hours for hepatic impaired patients

  10. Urine pharmacokinetics: amount excreted (Ae)

    for elafibranor and metabolites, if applicable. 24 hours urine collection from dosing to 216 hours post-dose

    Time frame: pre-dose and then 24, 48, 72, 96, 120, 144, 168, 192, 216 hours post-dose

  11. Urine pharmacokinetics: cumulative amount excreted (Ae0-t)

    for elafibranor and metabolites, if applicable. 24 hours urine collection from dosing to 216 hours post-dose

    Time frame: pre-dose and then 24, 48, 72, 96, 120, 144, 168, 192, 216 hours post-dose

  12. Urine pharmacokinetics: percentage of dose excreted (Fe)

    for elafibranor and metabolites, if applicable. 24 hours urine collection from dosing to 216 hours post-dose

    Time frame: pre-dose and then 24, 48, 72, 96, 120, 144, 168, 192, 216 hours post-dose

  13. Urine pharmacokinetics: cumulative percent of dose excreted (Fe0-t)

    for elafibranor and metabolites, if applicable. 24 hours urine collection from dosing to 216 hours post-dose

    Time frame: pre-dose and then 24, 48, 72, 96, 120, 144, 168, 192, 216 hours post-dose

  14. Urine pharmacokinetics: renal clearance (CLR)

    for elafibranor and metabolites, if applicable. 24 hours urine collection from dosing to 216 hours post-dose

    Time frame: pre-dose and then 24, 48, 72, 96, 120, 144, 168, 192, 216 hours post-dose

07

Study locations

2 sites
  • Division of Clinical Pharmacology, University of Miami
    Miami, Florida 33136, United States
  • inVentiv Health Clinical Research
    Miami, Florida 33136, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Jun 2019, 5 months.

Of 48 industry-sponsored phase 1 interventional studies under Liver Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 5 months is below that.

Counting every sponsor, half of 53 studies reached it within 14 months; a quarter within 5 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2018
First posted
Dec 5, 2018
StartActual
Dec 12, 2018
Primary completionActual
Jun 7, 2019
CompletionActual
Jun 14, 2019
Last update
Aug 22, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03765671
Lead sponsor
Genfit
Collaborators
Syneos Health, University of Miami
Responsible party
Sponsor
First posted
Dec 5, 2018
Start date
Dec 12, 2018
Primary completion
Jun 7, 2019
Completion
Jun 14, 2019
Last update
Aug 22, 2019

Study contacts

Pascal BIRMAN, MD
study director · Genfit

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elifibranor

Start the discussion